These results indicate osimertinib demonstrates better efficacy and less side effects, as well as CNS penetration, making it the new standard first-line treatment for mutated EGFR advanced NSCLC patients [9]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.